Live attenuated and inactivated viral vaccine formulation and nasal delivery: Potential and challenges

Advanced Drug Delivery Reviews

Volumn 93, Issue , 2015, Pages 56-78

  Tlaxca, José L ^a   Ellis, Scott ^b   Remmele, Richard L ^a  

^a MEDIMMUNE   (United States)

^b GILEAD SCIENCES   (United States)

Author keywords

Drug delivery; Formulation; Killed inactivated; Live attenuated; Nasal; Stability; Vaccines

Indexed keywords

CONTROLLED DRUG DELIVERY; CONVERGENCE OF NUMERICAL METHODS; COST EFFECTIVENESS; DRUG DELIVERY; TARGETED DRUG DELIVERY; VACCINES;

CELL-MEDIATED IMMUNE; FORMULATION; FORMULATION DEVELOPMENT; KILLED-INACTIVATED; LIVE ATTENUATED VACCINES; LIVE-ATTENUATED; NASAL; VACCINE DEVELOPMENT;

DISEASES;

BCG VACCINE; CHICKENPOX MEASLES MUMPS RUBELLA VACCINE; CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS A VACCINE; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; JAPANESE ENCEPHALITIS VACCINE; LIVE VACCINE; MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE; MENINGOCOCCUS VACCINE; POLIOMYELITIS VACCINE; RABIES VACCINE; ROTAVIRUS VACCINE; SMALLPOX VACCINE; TYPHOID VACCINE; VARICELLA ZOSTER VACCINE; YELLOW FEVER VACCINE; VIRUS VACCINE;

ADSORPTION; DEAMINATION; DENATURATION; DRUG FORMULATION; DRUG STABILITY; DRUG STORAGE; DRY POWDER; FREEZE DRYING; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; NONHUMAN; NOSE IRRITATION; OXIDATION; PRECIPITATION; PRIORITY JOURNAL; REVIEW; SHELF LIFE; SPRAY DRYING; VIRUS INACTIVATION; ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG DESIGN; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; MEDICINAL CHEMISTRY; PROCEDURES;

ADMINISTRATION, INTRANASAL; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG STABILITY; HUMANS; VACCINES, ATTENUATED; VIRAL VACCINES;

EID: 84945494503     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2014.10.002     Document Type: Review

References (128)

1. Zeng Y., Fan H., Chiueh G., Pham B., Martin R., Lechuga-Ballesteros D., Truong V.L., Joshi S.B., Middaugh C.R. Towards development of stable formulations of a live attenuated bacterial vaccine: a preformulation study facilitated by a biophysical approach. Hum. Vaccin. 2009, 5:322-331.
2. Mielcarek N., Debrie A.S., Raze D., Bertout J., Rouanet C., Younes A.B., Creusy C., Engle J., Goldman W.E., Locht C. Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough. PLoS Pathog. 2006, 2:e65.
3. Alexander L.N., Seward J.F., Santibanez T.A., Pallansch M.A., Kew O.M., Prevots D.R., Strebel P.M., Cono J., Wharton M., Orenstein W.A., Sutter R.W. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA 2004, 292:1696-1701.
4. C.f.D.C.a.Prevention Suspension of rotavirus vaccine after reports of intussusception-United States, 1999. MMWR Morb. Mortal. Wkly Rep. 2004, 53(37):789.
5. Kalvodova L., Sampaio J.L., Cordo S., Ejsing C.S., Shevchenko A., Simons K. The lipidomes of vesicular stomatitis virus, semliki forest virus, and the host plasma membrane analyzed by quantitative shotgun mass spectrometry. J. Virol. 2009, 83:7996-8003.
6. Klenk H.D., Choppin P.W. Glycolipid content of vesicular stomatitis virus grown in baby hamster kidney cells. J. Virol. 1971, 7:416-417.
7. Huang R.T. Involvement of glycolipids in myxovirus-induced membrane fusion (haemolysis). J. Gen. Virol. 1983, 64(Pt 1):221-224.
8. Huang R.T. The role of neutral glycolipids and phospholipids in myxovirus-induced membrane fusion. Lipids 1983, 18:489-492.
9. Aloia R.C., Tian H., Jensen F.C. Lipid composition and fluidity of the human immunodeficiency virus envelope and host cell plasma membranes. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:5181-5185.
10. Baxter D. Active and passive immunity, vaccine types, excipients and licensing. Occup. Med. (Lond.) 2007, 57:552-556.
11. Batista-Duharte A., Lindblad E.B., Oviedo-Orta E. Progress in understanding adjuvant immunotoxicity mechanisms. Toxicol. Lett. 2011, 203:97-105.
12. Buonaguro L., Wang E., Tornesello M.L., Buonaguro F.M., Marincola F.M. Systems biology applied to vaccine and immunotherapy development. BMC Syst Biol 2011, 5:146.
13. Steinman R.M., Hawiger D., Nussenzweig M.C. Tolerogenic dendritic cells. Annu. Rev. Immunol. 2003, 21:685-711.
14. Heath W.R., Belz G.T., Behrens G.M., Smith C.M., Forehan S.P., Parish I.A., Davey G.M., Wilson N.S., Carbone F.R., Villadangos J.A. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol. Rev. 2004, 199:9-26.
15. Sallusto F., Lanzavecchia A., Araki K., Ahmed R. From vaccines to memory and back. Immunity 2010, 33:451-463.
16. Garcon N., Van Mechelen M. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev Vaccines 2010, 10:471-486.
17. Lanzavecchia A., Sallusto F. Human B cell memory. Curr. Opin. Immunol. 2009, 21:298-304.
18. Einstein M.H., Baron M., Levin M.J., Chatterjee A., Edwards R.P., Zepp F., Carletti I., Dessy F.J., Trofa A.F., Schuind A., Dubin G. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum. Vaccin. 2009, 5:705-719.
19. Belshe R.B., Ambrose C.S., Yi T. Safety and efficacy of live attenuated influenza vaccine in children 2-7 years of age. Vaccine 2008, 26(Suppl. 4):D10-D16.
20. Swayne D.E., Beck J.R. Heat inactivation of avian influenza and Newcastle disease viruses in egg products. Avian Pathol. 2004, 33:512-518.
21. Purifoy D.J., Purifoy J.A., Sagik B.P. A mathematical analysis of concomitant virus replication and heat inactivation. J. Virol. 1968, 2:275-280.
22. Laird D.T., Sun Y., Reineke K.F., Shieh Y.C. Effective hepatitis A virus inactivation during low-heat dehydration of contaminated green onions. Food Microbiol 2011, 28:998-1002.
23. Mattle M.J., Crouzy B., Brennecke M., Wigginton K.R., Perona P., Kohn T. Impact of virus aggregation on inactivation by peracetic acid and implications for other disinfectants. Environ Sci Technol 2011, 45:7710-7717.
24. Quan F.S., Li Z.N., Kim M.C., Yang D., Compans R.W., Steinhauer D.A., Kang S.M. Immunogenicity of low-pH treated whole viral influenza vaccine. Virology 2011, 417:196-202.
25. Ohtake S., Martin R.A., Yee L., Chen D., Kristensen D.D., Lechuga-Ballesteros D., Truong-Le V. Heat-stable measles vaccine produced by spray drying. Vaccine 2009, 28:1275-1284.
26. Stadler M., Gruber G., Kannicht C., Biesert L., Radomski K.U., Suhartono H., Pock K., Neisser-Svae A., Weinberger J., Romisch J., Svae T.E. Characterisation of a novel high-purity, double virus inactivated von Willebrand Factor and Factor VIII concentrate (Wilate). Biologicals 2006, 34:281-288.
27. Biesert L., Suhartono H., Klengel R. Viral safety of a novel von Willebrand factor and factor VIII concentrate: virus inactivation capacities of optimized solvent/detergent and terminal dry-heat treatments. Haemostaseologie 2005, 110.
28. Ohtake S., Arakawa T., Koyama A.H. Arginine as a synergistic virucidal agent. Molecules 2010, 15:1408-1424.
29. Tsujimoto K., Uozaki M., Ikeda K., Yamazaki H., Utsunomiya H., Ichinose M., Koyama A.H., Arakawa T. Solvent-induced virus inactivation by acidic arginine solution. Int J Mol Med 2010, 25:433-437.
30. Colobert L. Sensitivity of poliomyelitis virus to catalytic systems generating free hydroxyl radicals. Rev. Pathol. Gen. Physiol. Clin. 1962, 62:551-555.
31. Manzi C., Enrich J., Ebner H., Dullinger R., Krumschnabel G. Copper induced formation of reactive oxygen species causes cell death and disruption of calcium homeostasis in trout hepatocytes. Toxicology 2004, 196:57-64.
32. Thurman R.B., Gerba C.P. The molecular mechanism of copper and silver ion disinfection of bacteria and viruses. CRC Crit. Rev. Environ. Control. 1989, 18:295-315.
33. Vasudevachari M.B., Antony A. Inhibition of avian myeloblastosis virus reverse transcriptase and virus inactivation by metal complexes of isonicotinic acid hydrazide. Antiviral Res. 1982, 2:291-300.
34. Trouwborst T., Kuyper S., de Jong J.C., Plantinga A.D. Inactivation of some bacterial and animal viruses by exposure to liquid-air interfaces. J. Gen. Virol. 1974, 24:155-165.
35. Kuwahara J., Suzuki T., Funakoshi K., Sugiura Y. Photosensitive DNA cleavage and phage inactivation by copper(II)-camptothecin. Biochemistry 1986, 25:1216-1221.
36. Kumar V., Lockerbie O., Keil S.D., Ruane P.H., Platz M.S., Martin C.B., Ravanat J.L., Cadet J., Goodrich R.P. Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level. Photochem. Photobiol. 2004, 80:15-21.
37. Pruss A., Kao M., von Garrel T., Frommelt L., Gurtler L., Benedix F., Pauli G. Virus inactivation in bone tissue transplants (femoral heads) by moist heat with the 'Marburg bone bank system'. Biologicals 2003, 31:75-82.
38. Repetto M., Semprine J., Boveris A. Lipid peroxidation: chemical mechanism, biological implications and analytical determination 2012, 3-30. InTech, (chapter 1).
39. Muik B., Lendl B., Molina-Diaz A., Ayora-Canada M.J. Direct monitoring of lipid oxidation in edible oils by Fourier transform Raman spectroscopy. Chem. Phys. Lipids 2005, 134:173-182.
40. Nawar W.W. Thermal degradation of lipids. A review. J. Agric. Food Chem. 1969, 17:18-21.
41. Leslie S.B., Israeli E., Lighthart B., Crowe J.H., Crowe L.M. Trehalose and sucrose protect both membranes and proteins in intact bacteria during drying. Appl. Environ. Microbiol. 1995, 61:3592-3597.
42. Chang B.S., Reeder G., Carpenter J.F. Development of a stable freeze-dried formulation of recombinant human interleukin-1 receptor antagonist. Pharm. Res. 1996, 13:243-249.
43. Crowe J.H., Carpenter J.F., Crowe L.M. The role of vitrification in anhydrobiosis. Annu. Rev. Physiol. 1998, 60:73-103.
44. Wiggan O., Livengood J.A., Silengo S.J., Kinney R.M., Osorio J.E., Huang C.Y., Stinchcomb D.T. Novel formulations enhance the thermal stability of live-attenuated flavivirus vaccines. Vaccine 2011, 29:7456-7462.
45. Singh A.K., Singh A., Madhav N.V.S. Nasal cavity: a promising transmucosal platform for drug delivery and research approaches from nasal to brain targeting. J. Drug Del. Ther. 2012, 2:22-33.
46. Turner P.V., Pekow C., Vasbinder M.A., Brabb T. Administration of substances to laboratory animals: equipment considerations, vehicle selection, and solute preparation. J Am Assoc Lab Anim Sci 2011, 50:614-627.
47. W.H.Organization Guidelines on Stability Evaluation of Vaccines, WHO/BS/06 2006, (2049-Final).
48. Padmavathi M. Preparation of rotavirus culture and quantification assays for the vaccine production and its role in vaccination. J. Chem. Bio. Phy. Sci. Sec A 2013, 3:1142-1148.
49. P.K., Gombold J., Gavin D., Wei Z., Baradaran K., Mire-Sluis A., Schenerman M. Lot release and characterization testing of live-virus-based vaccines and gene therapy products, part 2. BioProcess Int. 2011, 4:56-65.
50. Wood D.J., Macadam A.J. Laboratory tests for live attenuated poliovirus vaccines. Biologicals 1997, 25:3-15.
51. W.H.Organization Requirements for polio-myelitis vaccine (oral). Technical Report Series 1990 1990, 800:30-86.
52. Kramer B., Bruckner L., Daas A., Milne C. Collaborative study for validation of a serological potency assay for rabies vaccine (inactivated) for veterinary use. Pharmeur. Bio Sci. Notes 2010, 37-55.
53. Claassen I., Maas R., Oei H., Daas A., Milne C. Validation study to evaluate the reproducibility of a candidate in vitro potency assay of Newcastle disease vaccines and to establish the suitability of a candidate biological reference preparation. Pharmeur. Bio 2004, 2004:1-15.
54. Williams M.S. Single-radial-immunodiffusion as an in vitro potency assay for human inactivated viral vaccines. Vet. Microbiol. 1993, 37:253-262.
55. Wood J.M., Schild G.C., Newman R.W., Seagroatt V. An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines. J. Biol. Stand. 1977, 5:237-247.
56. Shank-Retzlaff M., Wang F., Morley T., Anderson C., Hamm M., Brown M., Rowland K., Pancari G., Zorman J., Lowe R., Schultz L., Teyral J., Capen R., Oswald C.B., Wang Y., Washabaugh M., Jansen K., Sitrin R. Correlation between mouse potency and in vitro relative potency for human papillomavirus Type 16 virus-like particles and Gardasil vaccine samples. Hum. Vaccin. 2005, 1:191-197.
57. Pombo M., Berthold I., Gingrich E., Jaramillo M., Leef M., Sirota L., Hsu H., Arciniega J. Validation of an anti-PA-ELISA for the potency testing of anthrax vaccine in mice. Biologicals 2004, 32:157-163.
58. Remmele R.L., Krishnan S., Callahan W.J. Development of stable lyophilized protein drug products. Curr Pharm Biotechnol 2012, 13:471-496.
59. Strambini G.B., Gabellieri E. Proteins in frozen solutions: evidence of ice-induced partial unfolding. Biophys. J. 1996, 70:971-976.
60. Curtis J.E., Nanda H., Khodadadi S., Cicerone M., Lee H.J., McAuley A., Krueger S. Small-angle neutron scattering study of protein crowding in liquid and solid phases: lysozyme in aqueous solution, frozen solution, and carbohydrate powders. J Phys Chem B 2012, 116:9653-9667.
61. Cicerone M.T., Douglas J.F. β-Relaxation governs protein stability in sugar-glass matrices. Soft Matter 2012, 8.
62. Dohnalkova A.C., Marshall M.J., Arey B.W., Williams K.H., Buck E.C., Fredrickson J.K. Imaging hydrated microbial extracellular polymers: comparative analysis by electron microscopy. Appl Environ Microbiol 2010, 77:1254-1262.
63. Crowe J.H., Crowe L.M., Carpenter J.F., Aurell Wistrom C. Stabilization of dry phospholipid bilayers and proteins by sugars. Biochem. J. 1987, 242:1-10.
64. Adebayo A.A., Sim-Brandenburg J.W., Emmel H., Olaleye D.O., Niedrig M. Stability of 17D yellow fever virus vaccine using different stabilizers. Biologicals 1998, 26:309-316.
65. Forconi M., Herschlag D. Metal ion-based RNA cleavage as a structural probe. Methods Enzymol. 2009, 468:91-106.
66. Tannock G.A., Hierholzer J.C., Bryce D.A., Chee C.F., Paul J.A. Freeze-drying of respiratory syncytial viruses for transportation and storage. J. Clin. Microbiol. 1987, 25:1769-1771.
67. Jin T.H., Tsao E., Goudsmit J., Dheenadhayalan V., Sadoff J. Stabilizing formulations for inhalable powders of an adenovirus 35-vectored tuberculosis (TB) vaccine (AERAS-402). Vaccine 2010, 28:4369-4375.
68. Saluja V., Amorij J.P., Kapteyn J.C., de Boer A.H., Frijlink H.W., Hinrichs W.L. A comparison between spray drying and spray freeze drying to produce an influenza subunit vaccine powder for inhalation. J Control Release 2010, 144:127-133.
69. Vehring R. Pharmaceutical particle engineering via spray drying. Pharm. Res. 2008, 25:999-1022.
70. Maa Y.F., Nguyen P.A., Andya J.D., Dasovich N., Sweeney T.D., Shire S.J., Hsu C.C. Effect of spray drying and subsequent processing conditions on residual moisture content and physical/biochemical stability of protein inhalation powders. Pharm. Res. 1998, 15:768-775.
71. Maury M., Murphy K., Kumar S., Mauerer A., Lee G. Spray-drying of proteins: effects of sorbitol and trehalose on aggregation and FT-IR amide I spectrum of an immunoglobulin G. Eur. J. Pharm. Biopharm. 2005, 59:251-261.
72. Hajare A., More H., Pisal S. Vacuum foam drying: a new technology for preserving sensitive biomolecules. Eur. Ind. Pharm. 2009, 10-18.
73. Pisal S.S., Wawde G.M., Bandivadekar M.M., Hajare A.A., More H.N., Kadam S.S. Vacuum foam drying for preservation of lasota virus: screening of foaming agent and cycle optimization. Indian J. Biotechnol. 2006, 5:491-497.
74. Chen J., Park H., Park K. Synthesis of superporous hydrogels: hydrogels with fast swelling and superabsorbent properties. J. Biomed. Mater. Res. 1999, 44:53-62.
75. Abdul-Fattah A.M., Truong-Le V., Yee L., Pan E., Ao Y., Kalonia D.S., Pikal M.J. Drying-induced variations in physico-chemical properties of amorphous pharmaceuticals and their impact on Stability II: stability of a vaccine. Pharm. Res. 2007, 24:715-727.
76. Empey K.M., Peebles R.S., Kolls J.K. Pharmacologic advances in the treatment and prevention of respiratory syncytial virus. Clin Infect Dis 2010, 50:1258-1267.
77. Levine M.M. Immunization against bacterial diseases of the intestine. J. Pediatr. Gastroenterol. Nutr. 2000, 31:336-355.
78. Lamm M.E. Interaction of antigens and antibodies at mucosal surfaces. Annu. Rev. Microbiol. 1997, 51:311-340.
79. He X.W., Wang F., Jiang L., Li J., Liu S.K., Xiao Z.Y., Jin X.Q., Zhang Y.N., He Y., Li K., Guo Y.J., Sun S.H. Induction of mucosal and systemic immune response by single-dose oral immunization with biodegradable microparticles containing DNA encoding HBsAg. J. Gen. Virol. 2005, 86:601-610.
80. Hutin Y.J., Hauri A.M., Armstrong G.L. Use of injections in healthcare settings worldwide, 2000: literature review and regional estimates. BMJ 2003, 327:1075.
81. Kupper T.S., Fuhlbrigge R.C. Immune surveillance in the skin: mechanisms and clinical consequences. Nat. Rev. Immunol. 2004, 4:211-222.
82. Williams J., Fox-Leyva L., Christensen C., Fisher D., Schlicting E., Snowball M., Negus S., Mayers J., Koller R., Stout R. Hepatitis A vaccine administration: comparison between jet-injector and needle injection. Vaccine 2000, 18:1939-1943.
83. Kendall M., Mitchell T., Wrighton-Smith P. Intradermal ballistic delivery of micro-particles into excised human skin for pharmaceutical applications. J. Biomech. 2004, 37:1733-1741.
84. Zhang L., Nolan E., Kreitschitz S., Rabussay D.P. Enhanced delivery of naked DNA to the skin by non-invasive in vivo electroporation. Biochim. Biophys. Acta 2002, 1572:1-9.
85. Tezel A., Paliwal S., Shen Z., Mitragotri S. Low-frequency ultrasound as a transcutaneous immunization adjuvant. Vaccine 2005, 23:3800-3807.
86. Bramson J., Dayball K., Evelegh C., Wan Y.H., Page D., Smith A. Enabling topical immunization via microporation: a novel method for pain-free and needle-free delivery of adenovirus-based vaccines. Gene Ther. 2003, 10:251-260.
87. Prausnitz M.R. Microneedles for transdermal drug delivery. Adv. Drug Deliv. Rev. 2004, 56:581-587.
88. Neutra M.R., Kozlowski P.A. Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol. 2006, 6:148-158.
89. Hassan F., Nuovo G.J., Crawford M., Boyaka P.N., Kirkby S., Nana-Sinkam S.P., Cormet-Boyaka E. MiR-101 and miR-144 regulate the expression of the CFTR chloride channel in the lung. PLoS One 2012, 7:e50837.
90. Boyaka P.N., Tafaro A., Fischer R., Leppla S.H., Fujihashi K., McGhee J.R. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen. J. Immunol. 2003, 170:5636-5643.
91. Wu H.Y., Nguyen H.H., Russell M.W. Nasal lymphoid tissue (NALT) as a mucosal immune inductive site. Scand. J. Immunol. 1997, 46:506-513.
92. Kuper C.F., Koornstra P.J., Hameleers D.M., Biewenga J., Spit B.J., Duijvestijn A.M., van Breda Vriesman P.J., Sminia T. The role of nasopharyngeal lymphoid tissue. Immunol. Today 1992, 13:219-224.
93. Vidgren M.T., Kublik H. Nasal delivery systems and their effect on deposition and absorption. Adv. Drug Deliv. Rev. 1998, 29:157-177.
94. Mutsch M., Zhou W., Rhodes P., Bopp M., Chen R.T., Linder T., Spyr C., Steffen R. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N. Engl. J. Med. 2004, 350:896-903.
95. Hamada H., Hiroi T., Nishiyama Y., Takahashi H., Masunaga Y., Hachimura S., Kaminogawa S., Takahashi-Iwanaga H., Iwanaga T., Kiyono H., Yamamoto H., Ishikawa H. Identification of multiple isolated lymphoid follicles on the antimesenteric wall of the mouse small intestine. J. Immunol. 2002, 168:57-64.
96. Mowat A.M. Anatomical basis of tolerance and immunity to intestinal antigens. Nat. Rev. Immunol. 2003, 3:331-341.
97. Fooks A.R. Development of oral vaccines for human use. Curr. Opin. Mol. Ther. 2000, 2:80-86.
98. Brown W.R. Enteric immunization: promises and challenges. Dig. Dis. 1996, 14:192-200.
99. Soane R.J., Frier M., Perkins A.C., Jones N.S., Davis S.S., Illum L. Evaluation of the clearance characteristics of bioadhesive systems in humans. Int. J. Pharm. 1999, 178:55-65.
100. Costantino H.R., Illum L., Brandt G., Johnson P.H., Quay S.C. Intranasal delivery: physicochemical and therapeutic aspects. Int. J. Pharm. 2007, 337:1-24.
101. Djupesland P.G. Nasal drug delivery devices: characteristics and performance in a clinical perspective-a review. Drug Deliv Transl Res 2012, 3:42-62.
102. Scherlie R. In vitro particle deposition in the nasal cavity. Inhal. Mag. 2011, 14-18.
103. Vetter A., Augustijns P., Bernkop-Schnurch A. Solubilizing agents in nasal formulations and their effect on ciliary beat frequency. Toxicol In Vitro 2011, 26:150-156.
104. Pires A., Fortuna A., Alves G., Falcao A. Intranasal drug delivery: how, why and what for?. J. Pharm. Pharm. Sci. 2009, 12:288-311.
105. Illum L., Jabbal-Gill I., Hinchcliffe M., Fisher A.N., Davis S.S. Chitosan as a novel nasal delivery system for vaccines. Adv. Drug Deliv. Rev. 2001, 51:81-96.
106. Kemble G., Greenberg H. Novel generations of influenza vaccines. Vaccine 2003, 21:1789-1795.
107. Garmise R.J., Staats H.F., Hickey A.J. Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination. AAPS PharmSciTech 2007, 8:E81.
108. U.FDA Guidance for Industry: Bioavailability and Bioequivalence Studies for Nasal Aerosols and Nasal Sprays for Local Action, Draft Guidance 2003.
109. Proctor D.F., Andersen I.H.P. The nose, upper airways physiology and the atmospheric environment 1982, Elsevier Biomedical Press, New York.
110. Mitchell J.P., Nagel M.W. Cascade impactors for the size characterization of aerosols from medical inhalers: their uses and limitations. J. Aerosol Med. 2003, 16:341-377.
111. Vila A., Sanchez A., Tobio M., Calvo P., Alonso M.J. Design of biodegradable particles for protein delivery. J. Control. Release 2002, 78:15-24.
112. Nagamoto T., Hattori Y., Takayama K., Maitani Y. Novel chitosan particles and chitosan-coated emulsions inducing immune response via intranasal vaccine delivery. Pharm. Res. 2004, 21:671-674.
113. Koping-Hoggard M., Sanchez A., Alonso M.J. Nanoparticles as carriers for nasal vaccine delivery. Expert Rev. Vaccines 2005, 4:185-196.
114. Andersen I., Proctor D.F. Measurement of nasal mucociliary clearance. Eur. J. Respir. Dis. 1983, 64:37-40.
115. Ali M.S., Pearson J.P. Upper airway mucin gene expression: a review. Laryngoscope 2007, 117:932-938.
116. van der Lubben I.M., Verhoef J.C., Borchard G., Junginger H.E. Chitosan for mucosal vaccination. Adv. Drug Deliv. Rev. 2001, 52:139-144.
117. Artursson P., Lindmark T., Davis S.S., Illum L. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm. Res. 1994, 11:1358-1361.
118. Baeyens V., Gurny R. Chemical and physical parameters of tears relevant for the design of ocular drug delivery formulations. Pharm. Acta Helv. 1997, 72:191-202.
119. Jaganathan K.S., Rao Y.U., Singh P., Prabakaran D., Gupta S., Jain A., Vyas S.P. Development of a single dose tetanus toxoid formulation based on polymeric microspheres: a comparative study of poly(D, L-lactic-co-glycolic acid) versus chitosan microspheres. Int. J. Pharm. 2005, 294:23-32.
120. von Hoegen P. Synthetic biomimetic supra molecular biovector (SMBV) particles for nasal vaccine delivery. Adv. Drug Deliv. Rev. 2001, 51:113-125.
121. Alpar H.O., Somavarapu S., Atuah K.N., Bramwell V.W. Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Adv. Drug Deliv. Rev. 2005, 57:411-430.
122. Debertin A.S., Tschernig T., Tonjes H., Kleemann W.J., Troger H.D., Pabst R. Nasal-associated lymphoid tissue (NALT): frequency and localization in young children. Clin. Exp. Immunol. 2003, 134:503-507.
123. Proctor D.F. Clearance of inhaled particles from the human nose. Arch. Intern. Med. 1973, 131(1):132-139.
124. Bouvier N.M., Lowen A.C. Animal Models for Influenza Virus Pathogenesis and Transmission. Viruses 2010, 2:1530-1563.
125. W.t.E.C.o.B.Standardization Guidelines on Nonclinical Evaluation of Vaccines, Mondiale De La Sante, Annex 1 2003.
126. U.FDA Guidance for Industry: Container Closure Systems for Packaging Human Drugs and Biologics, Chemistry, Manufacturing and Controls Documentation 1999.
127. U.FDA Guidance for Industry: Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products: Chemistry, Manufacturing and Controls Documentation 2002.
128. Norwood D.L., Paskiet D., Ruberto M., Feinberg T., Schroeder A., Poochikian G., Wang Q., Deng T.J., DeGrazio F., Munos M.K., Nagao L.M. Best practices for extractables and leachables in orally inhaled and nasal drug products: an overview of the PQRI recommendations. Pharm. Res. 2008, 25:727-739.